"Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia" was originally created and published by ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Canada NewsWire MONTREAL, Feb. 13, 2025 MONTREAL, Feb. 13, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...